Skip Navigation LinksHome > March 2014 - Volume 26 - Issue 2 > Smoothened inhibitors in the treatment of advanced basal cel...
Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000058
MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Reinhard Dummer

Smoothened inhibitors in the treatment of advanced basal cell carcinomas

Kunstfeld, Rainer

Collapse Box

Abstract

Purpose of review

The Hedgehog pathway has been identified as a key element in the development of many forms of cancer. Smoothened (Smo) inhibitors are known to beneficially interfere with the Hedgehog pathway and are currently under investigation as anticancer drugs for many tumor entities. Reviewed here are the most recent developments in clinical research on Smo inhibitors for the treatment of advanced basal cell carcinoma (BCC).

Recent findings

When reviewing the literature of the past 12 months, it is striking to see the rapid evolution of the field. Compounds that have been presented as powerful new drug candidates 12 months ago have now been discontinued, whereas new ones have emerged. Reports on 13 drug candidates have been identified: one marketed, vismodegib, eight currently under development (phase I–II) and four for which clinical investigation for BCC is currently not being pursued.

Summary

Smo inhibitors are a promising drug class for the treatment of BCC. To date, most candidates are in early stage development and are expected to enter the market in approximately 5–8 years, if successful.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.